Clinical Trials

NCT Number: NCT04363164 Phase: Phase 2 Trial Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Acronym:

NCT Number: NCT04471974 Phase: Phase 2 Trial Summary: This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other pla – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym:

NCT Number: NCT04631744 Phase: Phase 2 Trial Summary: The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym:

NCT Number: NCT04662580 Phase: Phase 1 Trial Summary: A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Ambrx, Inc. Acronym: ARX517

NCT Number: NCT04703920 Phase: Phase 1 Trial Summary: This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic B – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

NCT Number: NCT04754191 Phase: Phase 2 Trial Summary: This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic ca – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah Acronym: ENCORE

NCT Number: NCT04931823 Phase: Phase 1 Trial Summary: This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor a – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Conjupro Biotherapeutics, Inc. Acronym:

NCT Number: NCT04946370 Phase: Phase 1|Phase 2 Trial Summary: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym:

NCT Number: NCT04986423 Phase: Phase 2 Trial Summary: This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Zenith Epigenetics Acronym:

NCT Number: NCT05011188 Phase: Phase 1|Phase 2 Trial Summary: This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym: